"目录号: HY-15206
Membrane Transporter/Ion ChannelAutophagy-
Glibenclamide(Glyburide)是磺酰脲类化合物，能调节胰岛素的产生。
Potassium ChannelAutophagy
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Glibenclamide(Glyburide) is a sulfonylurea compound that modulates insulin production. IC50 value:Target:Sulfonylureas bind to ATP-dependent K+ channels in beta cells of the pancreas, depolarizing them and stimulating the release of Ca2+, which in turn stimulates insulin production. Glibenclamide, a sulphonylurea oral hypoglycaemic agent is a widely used antagonist of cromakalim-activated K+ channels in smooth muscle. Binding of Gli to SUR produces the closure of KATP channels and the inhibition of their activity. Glibenclamide is widely used for treatment of type 2-diabetes and it has been signaled as antiproliferative in several tumor cell lines.
Clinical Trial
NCT02830048
University of Oxford-Oxford University Hospitals NHS Trust
Diabetes Mellitus, Type 2
July 2016
Phase 2
NCT02145611
Dr. José Fernando Vilela-Martin MD PhD-Novartis-Hospital de Base
Type 2 Diabetes Mellitus-Hypertension-Endothelial Dysfunction
July 2013
Phase 4
NCT01867502
Hospital de Clinicas de Porto Alegre
Diabetes Mellitus, Type 2-Hypoglycemic Agents-Diabetic Blood Glucose Monitoring-Exercise
April 2014
Phase 4
NCT02318693
Merck Sharp & Dohme Corp.
Type 2 Diabetes Mellitus
February 4, 2015
Phase 4
NCT02919345
University of Campinas, Brazil-AstraZeneca
Diabetes Mellitus, Type 2-Coronary Artery Disease-Carotid Artery Diseases
January 2017
Phase 4
NCT01822548
Azienda Ospedaliero-Universitaria di Parma
Type 2 Diabetes
October 2010
Phase 3
NCT00515801
University Hospital, Basel, Switzerland
Diabetes Mellitus, Type 1
June 2007
Phase 2-Phase 3
NCT02080377
University of Edinburgh-Chief Scientist Office of the Scottish Government
Pregnancy-Gestational Diabetes
July 2014
Phase 3
NCT00734669
University of Giessen-Merck Sharp & Dohme Corp.
Type 2 Diabetes
July 2008
NCT00255541
AstraZeneca
Type 2 Diabetes
September 2004
Phase 3
NCT00610038
Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus
July 2006
Phase 2
NCT00267683
Novo Nordisk A/S
Diabetes-Diabetes Mellitus, Type 2
December 2005
Phase 3
NCT02375828
Assistance Publique - Hôpitaux de Paris
Neonatal Diabetes Secondary to Mutation in the Potassium Channel
March 2015
Phase 3
NCT03089333
University of Campinas, Brazil-Fundação de Amparo à Pesquisa do Estado de São Paulo
Hypertension-Diabetes Mellitus, Type 2-Blood Pressure-Obesity-Cardiac Hypertrophy-Microalbuminuria-Vascular Stiffness
July 2016
Phase 4
NCT02201602
Khoo Teck Puat Hospital
Diabetes
August 2014
Phase 4
NCT02128022
Papworth Hospital NHS Foundation Trust
Angina Pectoris
July 2014
Phase 1
NCT00770835
Takeda
Diabetes Mellitus
March 2009
Phase 4
NCT01145534
Federal University of Paraíba-Conselho Nacional de Desenvolvimento Científico e Tecnológico
Diabetes
January 2009
Phase 1-Phase 2
NCT00696982
Assaf-Harofeh Medical Center
Diabetes Mellitus-Arterial Stiffness
June 2008
NCT00393718
Novo Nordisk A/S
Diabetes-Diabetes Mellitus, Type 2
November 2006
Phase 3
NCT00472875
King's College Hospital NHS Trust
Type 1 Diabetes Mellitus
May 2007
Phase 4
NCT00251940
AstraZeneca
Type 2 Diabetes
July 2004
Phase 3
NCT00184821
Radboud University-Dutch Diabetes Fund
Diabetes Mellitus, Insulin-Dependent-Ischemia-Reperfusion Injury
June 2004
NCT02726490
Texas Tech University Health Sciences Center, El Paso
Gestational Diabetes
July 2016
NCT01733108
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
July 2008
Phase 1
NCT01454154
Remedy Pharmaceuticals, Inc.-U.S. Army Medical Research and Materiel Command-INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Traumatic Brain Injury
November 2011
Phase 2
NCT02815787
Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
March 2014
Phase 1
NCT01716338
Washington University School of Medicine-United States Department of Defense-University of Maryland
Healthy Volunteers
January 2013
Phase 1
NCT01794182
Remedy Pharmaceuticals, Inc.
Ischemic Stroke-Malignant Edema
May 2013
Phase 2
NCT00451620
University of British Columbia-Novo Nordisk A/S
Type 2 Diabetes
November 2003
Phase 2
NCT01268683
Remedy Pharmaceuticals, Inc.-University of Maryland-Massachusetts General Hospital
Ischemic Stroke
May 2011
Phase 1-Phase 2
NCT01456650
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type 2 Diabetes
March 2011
Phase 4
NCT00865436
Actavis Inc.
Healthy
April 2004
Phase 1
NCT00865241
Actavis Inc.
Healthy
November 2002
Phase 1
NCT00864734
Actavis Inc.
Healthy
November 2002
Phase 1
NCT00965991
University of New Mexico
Gestational Diabetes
July 2003
NCT02183428
Boehringer Ingelheim
Healthy
May 2008
Phase 1
NCT00835991
Teva Pharmaceuticals USA
Healthy
February 2003
Phase 1
NCT00836472
Teva Pharmaceuticals USA
Healthy
April 2003
Phase 1
NCT00744965
University of Texas Southwestern Medical Center
Mild Gestational Diabetes
August 2008
Phase 4
NCT00759720
Takeda
Diabetes Mellitus
November 2003
Phase 3
NCT02460874
University of Alabama at Birmingham
Cerebral Edema-Brain Metastases
September 2017
Phase 1-Phase 2
NCT00279045
GlaxoSmithKline
Diabetes Mellitus, Type 2
January 2000
Phase 3
NCT00494312
Takeda
Diabetes Mellitus-Liver
October 2000
Phase 4
NCT03078725
The University of Texas Health Science Center, Houston
Gestational Diabetes Mellitus, Class A2
March 20, 2017
Phase 4
NCT00521820
Takeda
Diabetes Mellitus
June 2000
Phase 3
NCT00160485
Tripler Army Medical Center
Gestational Diabetes
June 2004
Phase 4
NCT01329016
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-University of Washington-University of Pittsburgh-University of Texas-Indiana University School of Medicine-RTI International
Gestational Diabetes Mellitus
July 2011
Phase 1-Phase 2
NCT01731431
Assistance Publique - Hôpitaux de Paris
Diabetes-Gestational
January 2012